Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MKPR | ISIN: FR0010425595 | Ticker-Symbol: ZVA
Tradegate
15.04.24
15:52 Uhr
2,400 Euro
+0,015
+0,63 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLECTIS SA Chart 1 Jahr
5-Tage-Chart
CELLECTIS SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,3002,46515.04.
2,3602,40515.04.

Aktuelle News zur CELLECTIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs117NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
► Artikel lesen
08.04.Cellectis S.A. - 6-K, Report of foreign issuer2
04.04.Cellectis Inc.: Monthly information on share capital and company voting rights4
04.03.Cellectis Inc.: Monthly information on share capital and company voting rights7
02.02.Cellectis Inc.: Monthly information on share capital and company voting rights7
16.01.Cellectis draws down second tranche under EIB credit facility8
16.01.Cellectis S.A. - 6-K, Report of foreign issuer3
16.01.Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)6
08.01.Cellectis Inc.: Monthly information on share capital and company voting rights5
29.12.23Palatin Technologies, Cellectis among healthcare movers57
22.12.23Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023663NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
► Artikel lesen
22.12.23Cellectis S.A. - 6-K, Report of foreign issuer3
20.12.23TTOO, CGEN and CLLS are among pre market gainers42
05.12.23Cellectis S.A. - 6-K, Report of foreign issuer6
01.12.23Cellectis Inc.: Monthly information on share capital and company voting rights6
17.11.23Cellectis' Shareholders Meeting to be Held on December 22, 20237
15.11.23Cellectis S.A. - 6-K, Report of foreign issuer2
15.11.23Cellectis stock jumps on execution of $140M additional investment with AstraZeneca18
15.11.23Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca349Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders'...
► Artikel lesen
08.11.23CLLS, CMRX and NVOS are among pre market gainers10
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2